CD28 — gene · CancerIndex

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD28 Fusion1
Ipilimumab	Sezary SyndromeALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1520 A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protei… (full text at CIViC) PMID 25802883 · Sekulic et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (3)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Germ Cell Tumors and Shared Leukemias (MSK, J Clin Invest 2020) gct_msk_2020	unmapped	Ssm	1	20	5%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.
· Mol Genet Genomic Med · 2015 · PMID 25802883 · validated civic_curation pubmed